Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 03, 2015 6:58 PM ET

Pharmaceuticals

Company Overview of Adheron Therapeutics, Inc.

Company Overview

Adheron Therapeutics, Inc. develops pharmaceuticals for the treatment of rheumatoid arthritis and fibrotic diseases. Its product SDP051, is a Cad-11 antagonist that acts as an adhesive between cells and changes in these Cad-11 interactions can induce the cells to produce many proteins that influence the cellular environment positively or adversely. The company's product is used in pulmonary fibrosis and skin fibrosis. Adheron Therapeutics, Inc. was formerly known as Synovex Corporation. The company was incorporated in 2003 and is based in Berkeley, California.

2930 Domingo Avenue

Mail Boxes Plus

Mail Box 104

Berkeley, CA 94705

United States

Founded in 2003

Key Executives for Adheron Therapeutics, Inc.

Scientific Founder
Scientific Founder
Co-Founder and Director
Age: 75
Compensation as of Fiscal Year 2015.

Adheron Therapeutics, Inc. Key Developments

Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results

Adheron Therapeutics announced the completion of the company's Phase 1 clinical trial for its leading Cad-11 inhibitor SDP051. Cad-11 acts as a key mediator of joint destruction in rheumatoid arthritis, and is also an important contributor to fibrotic pathology. These are disease pathways that Adheron Therapeutics is particularly interested in pursuing. SDP051 is a humanized monoclonal antibody to Cadherin-11, which acts as an adhesive between cells. Changes in Cad-11 interactions can induce cells to produce proteins that influence the cellular environment. The recently completed SDP051 trial was designed to assess the safety and tolerability of an escalating single dose of the compound in healthy volunteers who received SDP051 or placebo. The trial also assessed the pharmacokinetic properties of the protein in vivo. Results from the Phase 1 trial show that SDP051 is safe and well-tolerated at doses up to 10 mg/kg per day with no evidence of significant side effects.

Similar Private Companies By Industry

Company Name Region
Alliance Pharmaceutical Corp. United States
ImmusanT, Inc. United States
Organon Teknika Corporation LLC United States
Beach Products Inc. United States
Disposition Company, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 17, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Adheron Therapeutics, Inc., please visit adherontherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.